| Autor: |
Shukuri M; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Onoe S; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Karube T; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Mokudai R; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Wakui H; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Asano H; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Murai S; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan., Akizawa H; Laboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan. |
| Abstrakt: |
Bradykinin B1 receptor (B1R) has garnered attention as a cancer therapeutic and diagnostic target. Several reports on radiolabelled derivatives of B1R antagonists have shown favourable properties as imaging agents in cells highly expressing hB1R following transfection. In the present study, we assessed whether radiolabelled probes can detect B1R endogenously expressed in cancer cells. To this end, we evaluated 111 In-labelled derivatives of a B1R antagonist ([ 111 In]In-DOTA-Ahx-R954) using glioblastoma cell lines (U87MG and U251MG) with different B1R expression levels. Cellular uptake studies showed that the specific accumulation of [ 111 In]In-DOTA-Ahx-R954 in U87MG was higher than that in U251MG, which correlated with B1R expression levels. Tissue distribution in U87MG-bearing mice revealed approximately 2-fold higher radioactivity in tumours than in the muscle in the contralateral leg. The specific accumulation of [ 111 In]In-DOTA-Ahx-R954 in the tumour was demonstrated by the reduction in the tumour-to-plasma ratios in nonlabelled R954-treated mice. Moreover, ex vivo autoradiographic images revealed that the intratumoural distribution of [ 111 In]In-DOTA-Ahx-R954 correlated with the localisation of B1R-expressing glioblastoma cells. In conclusion, we demonstrated that [ 111 In]In-DOTA-Ahx-R954 radioactivity correlated with B1R expression in glioblastoma cells, indicating that radiolabelled derivatives of the B1R antagonist could serve as promising tools for elucidating the involvement of B1R in cancer. |
